1. TCR engineered T cells for solid tumor immunotherapy.
- Author
-
Zhang, Yikai, Liu, Zhipeng, Wei, Wei, and Li, Yangqiu
- Subjects
- *
T cells , *T cell receptors , *IMMUNOTHERAPY , *CHIMERIC antigen receptors , *CELL membranes - Abstract
T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF